Patrizia Vici
A5010531543- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related Molecular Pathways
- Breast Lesions and Carcinomas
- Estrogen and related hormone effects
- Cancer Risks and Factors
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Chemotherapy-induced cardiotoxicity and mitigation
- Ovarian cancer diagnosis and treatment
- PI3K/AKT/mTOR signaling in cancer
- Metabolism, Diabetes, and Cancer
- DNA Repair Mechanisms
- Hippo pathway signaling and YAP/TAZ
- Global Cancer Incidence and Screening
- Lung Cancer Research Studies
- Cervical Cancer and HPV Research
- BRCA gene mutations in cancer
- COVID-19 and healthcare impacts
Istituti di Ricovero e Cura a Carattere Scientifico
2017-2025
Instituto Nazionale Tumori Regina Elena
2009-2024
Cancer Institute (WIA)
1997-2023
Istituto di Sessuologia Clinica
2011-2023
National Cancer Institute
2012-2022
Istituti Fisioterapici Ospitalieri
2015-2022
Fondazione IRCCS Istituto Nazionale dei Tumori
2019-2022
La Roche College
2020
Pfizer (United Kingdom)
2020
Roche (Switzerland)
2020
In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, clinically meaningful overall (OS) effect PD-L1-positive aTNBC. The KEYNOTE-355 trial adding pembrolizumab to chemotherapy aTNBC similar PFS effects. IMpassion131...
The immune system seems to play a fundamental role in breast cancer responsiveness chemotherapy. We investigated two peripheral indicators of immunity/inflammation, i.e. neutrophil lymphocyte ratio (NLR) and platelet (PLR), order reveal possible relationship with pathological complete response (pCR) patients early or locally advanced treated neoadjuvant chemotherapy (NACT).We retrospectively analyzed 373 consecutive affected by candidates NACT. blood cell count before starting NACT was...
From February 1983 to January 1985, 497 patients with advanced breast cancer were randomly allocated receive either epirubicin or doxorubicin in the following combination chemotherapy regimen: fluorouracil (5-FU) 500 mg/m2 intravenous (IV) on days 1 and 8; 50 IV day 1; cyclophosphamide (FEC FAC). Cycles repeated every 21 until progression cumulative doses of 700 for 550 doxorubicin. Dose reductions applied according standard criteria. Activity was evaluated 443 (222 FEC arm 221 FAC arm). The...
// Andrea Botticelli 1, 2 , Concetta Elisa Onesti Ilaria Zizzari 3 Bruna Cerbelli 4 Paolo Sciattella 5 Mario Occhipinti 1 Michela Roberto Francesca Di Pietro Adriana Bonifacino 6 Michele Ghidini 7 Patrizia Vici 8 Laura Pizzuti Chiara Napoletano Lidia Strigari 9 Giulia D'Amati Federica Mazzuca Marianna Nuti and Marchetti Medical Oncology Department, Sant'Andrea Hospital, Rome, Italy Department of Clinical Molecular Medicine, "Sapienza" University Experimental Radiological Oncological...
PURPOSE We conducted a randomized trial to evaluate primarily the cardioprotective effect of dexrazoxane (DEX) in patients with advanced breast cancer and soft tissue sarcomas (STS) treated high-dose epirubicin (EPI). wished also determine value radioimmunoscintigraphy (RIS) assessment anthracycline cardiotoxicity. PATIENTS AND METHODS Patients (n = 95) or STS 34) received EPI 160 mg/m2 by intravenous (I.V.) bolus every 3 weeks without DEX 1,000 I.V. Cardiac monitoring included multigated...
Abstract Background HER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, rapid introduction new therapeutics has led to approval pertuzumab combined with trastuzumab and taxane in first-line, emtansine (T-DM1) second-line. Thereby, evidence T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, data from some retrospective reports suggesting lower activity. The purpose present study...
Immune checkpoint inhibitors have revolutionized treatment and outcome of melanoma many other solid malignancies including non-small cell lung cancer (NSCLC) renal carcinoma (RCC). Unfortunately, only a minority patients long-term benefit, while the remaining demonstrate primary or acquired resistance. Recently, it has been demonstrated that prevalence programmed death-ligand 1 (PD-L1) tumor-infiltrating lymphocytes (TILs) varies based on anatomical site metastases. In particular, liver...
The advent of immune checkpoint inhibitors (ICIs) has considerably expanded the armamentarium against non-small cell lung cancer (NSCLC) contributing to reshaping treatment paradigms in advanced disease setting. While promising tissue- and plasma-based biomarkers are under investigation, no reliable predictive factor is currently available aid selection. Patients with stage IIIB–IV NSCLC receiving nivolumab at Sant'Andrea Hospital Regina Elena National Cancer Institute from June 2016 July...
To evaluate the comparative efficacy of varying intensity schedules recombinant human granulocyte colony-stimulating factor (G-CSF; filgrastim) support in preventing febrile neutropenia early breast cancer patients treated with relatively high-dose epirubicin plus cyclophosphamide (EC).From October 1991 to April 1994, 506 stage I and II were randomly assigned receive, a factorial 2 x design, 120 mg/m2 600 intravenously on day 1 every 21 days for 4 cycles +/- lonidamine G-CSF. The following...
// Patrizia Vici 1 , Laura Pizzuti Andrea Michelotti 2 Isabella Sperduti 3 Clara Natoli 4 Lucia Mentuccia 5 Luigi Di Lauro Domenico Sergi Paolo Marchetti 6 Daniele Santini 7 Emanuela Magnolfi Iezzi Luca Moscetti 8 Agnese Fabbri 9 Alessandra Cassano 10 Antonino Grassadonia Claudia Omarini 11 Federico Piacentini Botticelli Ilaria Bertolini Angelo Fedele Scinto 12 Germano Zampa 13 Maria Mauri 14 Loretta D'Onofrio Valentina Sini Maddalena Barba Marcello Maugeri-Saccà Ernesto Rossi Elisabetta...